Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572713 · ClinicalTrials.gov registry record
Systemic Synuclein Sampling Study (S4)
A clinical trial, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 80
- Enrollment target
NCT02572713: Completed study, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT02572713 is a clinical trial that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02572713 has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.
Primary Outcome
Blood will be analyzed using the most optimal, currently available, quantitative assays. The outcome will be expressed as a concentration of α-syn levels.
Interventions
- PROCEDURE Biofluid samplings
- PROCEDURE Tissue samplings
- DRUG DaTSCAN™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-08-01 |
What the finished NCT02572713 record still lists
NCT02572713 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Biofluid samplings is the first listed.
NCT02572713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02572713 about?
NCT02572713 is a clinical study titled "Systemic Synuclein Sampling Study (S4)". The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.
What is the current status of trial NCT02572713?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2015-10. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT02572713?
The interventions under investigation include: Biofluid samplings (PROCEDURE), Tissue samplings (PROCEDURE), DaTSCAN™ (DRUG).
Who is sponsoring clinical trial NCT02572713?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia